Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Opsens Inc T.OPS

OpSens Inc. is a medical device cardiology-focused company. The Company offers an advanced optical-based pressure guidewire that aims at improving the clinical outcome of patients with coronary artery disease. The Company’s segments include Medical and Industrial. The Medical segment focuses on physiological measurements, such as Fractional Flow Reserve (FFR) and Diastolic Pressure Ratio (dPR) in the coronary artery disease market and also supplies a range of miniature optical sensors to measure pressure and temperature to be used in a range of applications that can be integrated into other medical devices. The Industrial segment develops, manufactures and installs fiber optic sensing solutions for critical and demanding industrial applications. Its flagship product, the OptoWire, is a second-generation fiber optic pressure guidewire designed to provide the lowest drift in the industry and lesions access. It is approved for sale in the United States, European Union, Japan and Canada.


TSX:OPS - Post by User

Post by bossuon Jan 04, 2023 6:16pm
308 Views
Post# 35203832

Q1 Financial Report

Q1 Financial ReportShould announced Q1 FR in 48 hours..
I'm not expecting Big numbers but hope to see a better results than the Q1 2022
''Highlights for the quarter:

 

  • Consolidated sales of $8.1-million in Q1 2022, a decrease of 3 per cent compared with $8.3-million in Q1 2021; sales were negatively impacted by $400,000 due to unfavourable exchange rates and by the continuation of COVID-19-related impacts on the industry;
  • Net loss was $2.1-million in Q1 2022, compared with a net income of $600,000 in Q1 2021.
  • Opsens had $23.8-million in cash and cash equivalents as of Aug. 31, 2022.
  • Financing $ 11,5 M Q4
  • Cash and cash equivalent at $ 30 M or so at the end of the Q1 2023 .This is just the positive view on OPS
  • Sales $ 10 M ..from $ $ 8M
  • Just have been around to see the parking lot 50 % occupied !
  • Just demonstrating that the momentun is a non existant fact for now.
  • Share price action OK for now and the shareholders have to be ''PATIENT'' !
  • Let's see what Mr Laflamme will have to say at the FR  and should   provide guidance going forward !
<< Previous
Bullboard Posts
Next >>